| Name | Title | Contact Details |
|---|
Athol Savings Bank is a mutual savings bank based in Athol, Massachusetts. Our goal is to be the financial foundation in our community; working harder, reaching higher, and delivering strength, stability, and security to our customers. As we move forward, Athol Savings Bank is committed to being "A Solutions Bank" for our customers and the communities we serve. Member FDIC. Equal Housing Lender. Member DIF.
Atlas Battery Limited was incorporated as a public limited Company on October 19, 1966 and its shares are listed on Karachi and Lahore Stock Exchanges in Pakistan. The Company is engaged in manufacture and sales of AGS brand, automotive and motorcycle batteries. The Company has joint venture with GS Yuasa International. Atlas Battery Limited pioneered the manufacture of dry charged Hard Rubber batteries in Pakistan. The company has always been at the vanguard of development in the automotive industry in Pakistan making great strides in the fields research and development. The brand has, over the years, earned a solid reputation as a product of latest Japanese technology with consistently high levels of performance and reliability.
Kee Safety, Inc. is one of the worlds leading Safety Solutions Suppliers. We have been providing industry specific solutions such as railings, barriers, perimeter protection, fall prevention and many other applications since 1934. From Machine Guards to Roof Edge Fall Protection, Guardrailing to Pedestrian Barriers, Shop Fitting to Childrens Playgrounds, Kee Safety has supplied the answer to many problems with safe, reliable, cost effective and durable solutions. Please visit our website for more information.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.